Professional Publications

Lukas, J.; Bartkova, J.; Rohde, M.; Strauss, M.; Bartek, J.

Cyclin D1 is dispensable for G(1) control in retinoblastoma gene-deficient cells independently of cdk4 activity

[year of publication 2006, impact factor 10.498]

Haberichter, S.L.; Castaman, G.; Budde, U.; Peake, I.; Goodeve, A.; Rodeghiero, F.; Federici, A.B.; Batlle, J.; Meyer, D.; Mazurier, C.; Goudemand, J.; Eikenboom, J.; Schneppenheim, R.; Ingerslev, J.; Vorlova, Z.; Habart, D.; Holmberg, L.; Lethagen, S.; Pasi, J.; Hill, F.G.H.; Montgomery, R.R.

Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the european study: Molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)

[year of publication 2010, impact factor 10.432]

Castaman, G.; Lethagen, S.; Federici, AB.; Tosetto, A.; Goodeve, A.; Budde, U.; Batlle, J.; Meyer, D.; Mazurier, C.; Fressinaud, E.; Goudemand, J.; Eikenboom, J.; Schneppenheim, R.; Ingerslev, J.; Vorlova, Z.; Habart, D.; Holmberg, L.; Pasi, J.; Hill, F.; Peake, I.; Rodeghiero, F.

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD

[year of publication 2010, impact factor 10.432]

Forestier, E.; Izraeli, S.; Beverloo, B.; Haas, O.; Pession, A.; Michalová, K.; Stark, B.; Harrison, C.J.; Teigler-Schlegel, A.; Johansson, B.

Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome : an iBFM-SG study

[year of publication 2008, impact factor 10.432]

Porkka, K.; Koskenvesa, P.; Lundán, T.; Rimpiläinen, J.; Mustjoki, S.; Smykla, R.; Wild, R.; Luo, R.; Arnan, M.; Brethon, B.; Eccersley, L.; Hjorth-Hansen, H.; Höglund, M.; Klamová, H.; Knutsen, H.; Parikh, S.; Raffoux, E.; Gruber, F.; Brito-Babapulle, F.; Dombret, H.; Duarte, R.F.; Elonen, E.; Paquette, R.; Zwaan, C.M.; Lee, F.Y.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

[year of publication 2008, impact factor 10.432]

Ho, G.Y.F.; Burk, R.D.; Klein, S.; Kadish, A.S.; Chang, C.J.; Palan, P.; Basu, J.; Tachezy, R.; Lewis, R.; Romney, S.

Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia

[year of publication 2006, impact factor 10.165]

Germing, U.; Lauseker, M.; Hildebrandt, B.; Symeonidis, A.; Cermak, J.; Fenaux, P.; Kelaidi, C.; Pfeilstöcker, M.; Nösslinger, T.; Sekeres, M.; Maciejewski, J.; Haase, D.; Schanz, J.; Seymour, J.; Kenealy, M.; Weide, R.; Lübbert, M.; Platzbecker, U.; Valent, P.; Götze, K.; Stauder, R.; Blum, S.; Kreuzer, K.-A.; Schlenk, R.; Ganser, A.; Hofmann, W.-K.; Aul, C.; Krieger, O.; Kündgen, A.; Haas, R.; Hasford, J.; Giagounidis, A.

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study

[year of publication 2012, impact factor 10.164 ]

Curik, N.; Burda, P.; Vargova, K.; Pospisil, V.; Belickova, M.; Vlckova, P.; Savvulidi, F.; Necas, E.; Hajkova, H.; Haskovec, C.; Cermak, J.; Krivjanska, M.; Trneny, M.; Laslo, P.; Jonasova, A.; Stopka, T.

5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

[year of publication 2012, impact factor 10.164 ]

Kramarzova, K.; Stuchly, J.; Willasch, A.; Gruhn, B.; Schwarz, J.; Cermak, J.; Machova-Polakova, K.; Fuchs, O.; Stary, J.; Trka, J.; Boublikova, L.

Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences

[year of publication 2012, impact factor 10.164 ]

Crawley, CH.; Szydlo, R.; Lalancette, M.; Bacigalupo, A.; Lange, A.; Brune, M.; Juliusson, G.; Nagler, A.; Gratwohl, A.; Passweg, J.; Komarnicki, M.; Vítek, A.; Mayer, J.; Zander, A.; Sierra, J.; Rambaldi, A.; Ringden, O.; Niederwieser, D.; Apperley, J.F.:

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia : an analysis of prognostic factors from the Chronic leukemia working party of the EBMT.

[year of publication 2006, impact factor 10.131]

Stauder, R.; Yu, G.; Koinig, K.A.; Bagguley, T.; Fenaux, P.; Symeonidis, A.; Sanz, G.; Cermak, J.; et al.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

[year of publication 2018, impact factor 9.944 ]

de Swart, L.; Crouch, S.; Hoeks, M.; Smith, A.; Langemeijer, S.; Fenaux, P.; Symeonidis, A.; Čermák, J.; et al.

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

[year of publication 2020, impact factor 9.941 ]

Hoeks, M.; Yu, G.; Langemeijer, S.; Crouch, S.; de Swart, L.; Fenaux, P.; Symeonidis, A.; Čermák, J.; et al.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry

[year of publication 2020, impact factor 9.941 ]

Truxova, I.; Kasikova, L.; Salek, C.; et al.

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients

[year of publication 2020, impact factor 9.941 ]

Tiede, A.; Collins, P.; Knoebl, P.; Teitel, J.; Kessler, C.; Shima, M.; Di Minno, G.; D´ Oiron, R.; Salaj, P.; et al.

International recommendations on the diagnosis and treatment of acquired hemophilia

[year of publication 2020, impact factor 9.941 ]

de Witte, T.; Malcovati, L.; Fenaux, P.; Bowen, D.; Symeonidis, A.; Mittelman, M.; Stauder, R.; Sanz, G.; Čermák, J.; et al.

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome: the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

[year of publication 2020, impact factor 9.941 ]

Kayser, S.; Kramer M.; Martínez-Cuadrón, D.; Grenet, J.; Metzeler, K.H.; Sustkova, Z.; Luskin, M.R.; Brunner, A.M.; Elliott, M.A.; Gil, C.; Marini, S.C.; Ráčil, Z.; Cetkovsky, P.; et al.

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study

[year of publication 2022, impact factor 9.941 ]

Riedel, T.; Suttnar, J.; Brynda, E.; Houska, M.; Medved, L.; Dyr, J.E.

Fibrinopeptides A and B release in the process of surface fibrin formation.

[year of publication 2010, impact factor 9.898]

Soverini, S.; De Benedittis, C.; Machova Polakova, K.; Brouckova, A.; Horner, D.; Iacono, M.; Castagnetti, F.; Gugliotta, G.; Palandri, F.; Papayannidis, C.; Iacobucci, I.; Venturi, C.; Bochicchio, M.T.; Klamova, H.; Cattina, F.; Russo, D.; Bresciani, P.; Binotto, G.; Giannini, B.; Kohlmann, A.; Haferlach, T.; Roller, A.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

[year of publication 2013, impact factor 9.775 ]

Malcovati, L.; Hellström-Lindberg, E.; Bowen, D.; Ades, L.; Čermák, J.; Del Canizo, C.; Della Porta, M.G.; Fenaux, P.; Gattermann, N.; Germing, U.; Jansen, J.H.; Mittelman, M.; Mufti, G.; Platzbecker, U.; Sanz, G.F.; Selleslag, D.; Skov-Holm, M.; Stauder, R.; Symeonidis, A.; Van De Loosdrecht, A.A.; De Witte, T.; Cazzola, M.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

[year of publication 2013, impact factor 9.775 ]